ACOs need to provide comprehensive care management across a spectrum of provider specialties. To do this, they need a framework for evaluating potential partners that will help risk-bearing providers establish the partnerships that will enable them to achieve their goals.
As expected, pharmacy costs increased with the introduction of this new treatment in a market dominated by over-the-counter and generic treatments. On the other hand, outpatient GI-related and irritable bowel disease health care resource use and costs substantially decreased among commercial and Medicare patients following linaclotide treatment initiation.
The document “Feature and Function Recommendations To Optimize Clinician Usability of Direct Interoperability To Enhance Patient Care” offers recommendations from the clinician point of view. Widespread adoption of even a few of these recommendations by designers and vendors would greatly enhance care.
Studies comparing team care of diabetes with traditional care should be redesigned, say researchers. “In order for redesign studies to support generalization of their findings, methodology should include a randomized, controlled study design with intention-to-treat analysis,” the study states.
Accurate prognostic estimates can predict and document expected response to treatment, avoid ineffective and costly overtreatment, and facilitate meaningful discussions with lung cancer patients about the timing of best supportive care and hospice care when appropriate, thereby improving cancer care planning and quality scores.
Tuberous sclerosis complex (TSC) is a rare genetic disorder affecting the brain and other vital organs with varying symptoms and severity among patients. This study developed and validated a risk model to identify patients with TSC using large databases of medical and pharmacy claims.
One in five elderly patients returns to the hospital within 30 days of leaving. These rehospitalizations are a common and costly occurrence. A program developed to address problems in post-acute transitional care seems to be effective in reducing 30-day readmission rates for some Medicare fee-for-service beneficiaries.
Patients have a positive experience with IV infusions of infliximab within the BioAdvance PSP. The personnel and services associated with the program appear to be helpful to, and valued by, patients. The services enhance the overall treatment experience and potentially improve adherence and long-term health outcomes.